Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Pharm Des. 2013;19(4):614-23.

Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

Author information

  • 1Room 221, Department of Internal Medicine, University of Genoa, V.le Benedetto XV 6, 16132 Genoa, Italy.

Abstract

Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.

PMID:
23016857
[PubMed - indexed for MEDLINE]
PMCID:
PMC3549556
Free PMC Article

Images from this publication.See all images (3)Free text

Fig. (1)
Fig. (2)
Fig. (3)
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
    Loading ...
    Write to the Help Desk